72/120
3.0 / 5 stars
All 120 Win/Lose results shown below
NBIX Roast Me summary
NEUROCRINE BIOSCIENCES INC (NBIX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 9 wins, 3 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinNBIX / S&P 27.93% / 15.20% |
WinNBIX / S&P 34.42% / 15.00% |
WinNBIX / S&P 101.78% / 50.40% |
| 2026-Q12/3 |
LoseNBIX / S&P -7.11% / -4.33% |
WinNBIX / S&P 28.59% / 11.30% |
WinNBIX / S&P 120.00% / 27.70% |
| 2025-Q42/3 |
LoseNBIX / S&P 1.03% / 2.65% |
WinNBIX / S&P 21.45% / 9.00% |
WinNBIX / S&P 41.95% / 13.40% |
| 2025-Q32/3 |
WinNBIX / S&P 11.69% / 8.12% |
WinNBIX / S&P 19.61% / 4.61% |
LoseNBIX / S&P 11.47% / 13.45% |
| 2025-Q22/3 |
WinNBIX / S&P 13.64% / 10.94% |
WinNBIX / S&P 18.42% / 4.83% |
LoseNBIX / S&P 1.50% / 10.63% |
| 2025-Q11/3 |
LoseNBIX / S&P -18.97% / -4.27% |
WinNBIX / S&P 21.73% / 4.98% |
LoseNBIX / S&P -19.18% / 10.57% |
| 2024-Q43/3 |
WinNBIX / S&P 18.47% / 2.41% |
WinNBIX / S&P 24.81% / 5.25% |
WinNBIX / S&P 33.20% / 6.15% |
| 2024-Q32/3 |
LoseNBIX / S&P -16.31% / 5.89% |
WinNBIX / S&P 25.72% / 5.89% |
WinNBIX / S&P 100.53% / 6.11% |
| 2024-Q22/3 |
LoseNBIX / S&P -0.18% / 4.28% |
WinNBIX / S&P 26.69% / 5.38% |
WinNBIX / S&P 91.38% / 5.12% |
| 2024-Q12/3 |
LoseNBIX / S&P 4.68% / 10.56% |
WinNBIX / S&P 23.99% / 5.71% |
WinNBIX / S&P 498.36% / 5.59% |
| 2023-Q43/3 |
WinNBIX / S&P 17.12% / 11.69% |
WinNBIX / S&P 26.76% / 6.81% |
WinNBIX / S&P 58.33% / 7.78% |
| 2023-Q33/3 |
WinNBIX / S&P 19.30% / -3.27% |
WinNBIX / S&P 28.46% / 7.52% |
WinNBIX / S&P 222.41% / -5.03% |
| 2023-Q22/3 |
LoseNBIX / S&P -6.84% / 8.74% |
WinNBIX / S&P 29.01% / 9.50% |
WinNBIX / S&P 1350.00% / -8.57% |
| 2023-Q11/3 |
LoseNBIX / S&P -15.25% / 7.50% |
WinNBIX / S&P 32.38% / 10.77% |
LoseNBIX / S&P -16.44% / -15.69% |
| 2022-Q43/3 |
WinNBIX / S&P 12.46% / 7.56% |
WinNBIX / S&P 31.34% / 11.88% |
WinNBIX / S&P 69.57% / -17.99% |
| 2022-Q32/3 |
WinNBIX / S&P 8.96% / -4.88% |
WinNBIX / S&P 29.86% / 13.47% |
LoseNBIX / S&P -87.22% / -1.41% |
| 2022-Q22/3 |
WinNBIX / S&P 3.98% / -16.10% |
WinNBIX / S&P 25.67% / 13.71% |
LoseNBIX / S&P -96.75% / 11.04% |
| 2022-Q11/3 |
WinNBIX / S&P 10.07% / -4.60% |
LoseNBIX / S&P 15.51% / 15.97% |
LoseNBIX / S&P -82.06% / 42.23% |
| 2021-Q40/3 |
LoseNBIX / S&P -11.20% / 11.03% |
LoseNBIX / S&P 8.38% / 15.00% |
LoseNBIX / S&P -77.88% / 96.40% |
| 2021-Q31/3 |
LoseNBIX / S&P -1.45% / 0.58% |
LoseNBIX / S&P 2.62% / 10.77% |
WinNBIX / S&P 382.98% / 69.42% |
| 2021-Q21/3 |
LoseNBIX / S&P 0.07% / 8.55% |
LoseNBIX / S&P 2.61% / 6.58% |
WinNBIX / S&P 74.06% / 51.81% |
| 2021-Q12/3 |
LoseNBIX / S&P 1.46% / 6.17% |
WinNBIX / S&P 17.88% / -1.06% |
WinNBIX / S&P 120.00% / 7.39% |
| 2020-Q42/3 |
LoseNBIX / S&P -0.32% / 12.15% |
WinNBIX / S&P 32.71% / -3.72% |
WinNBIX / S&P 966.67% / -33.42% |
| 2020-Q32/3 |
LoseNBIX / S&P -21.18% / 8.93% |
WinNBIX / S&P 54.28% / -2.04% |
WinNBIX / S&P 452.94% / -27.10% |
| 2020-Q23/3 |
WinNBIX / S&P 40.96% / 20.54% |
WinNBIX / S&P 66.20% / -0.46% |
WinNBIX / S&P 1530.77% / -27.11% |
| 2020-Q12/3 |
WinNBIX / S&P -19.48% / -19.60% |
WinNBIX / S&P 71.03% / 3.47% |
LoseNBIX / S&P NBIX unavailable / -14.75% |
| 2019-Q43/3 |
WinNBIX / S&P 19.29% / 9.07% |
WinNBIX / S&P 74.67% / 5.36% |
WinNBIX / S&P 77.27% / 2.99% |
| 2019-Q32/3 |
WinNBIX / S&P 6.73% / 1.70% |
WinNBIX / S&P 63.05% / 5.02% |
LoseNBIX / S&P NBIX unavailable / 0.21% |
| 2019-Q21/3 |
LoseNBIX / S&P -4.17% / 4.30% |
WinNBIX / S&P 87.18% / 6.64% |
LoseNBIX / S&P NBIX unavailable / 8.65% |
| 2019-Q12/3 |
WinNBIX / S&P 23.37% / 13.65% |
WinNBIX / S&P 122.81% / 8.12% |
LoseNBIX / S&P NBIX unavailable / 14.29% |
| 2018-Q41/3 |
LoseNBIX / S&P -41.92% / -13.52% |
WinNBIX / S&P 179.16% / 9.05% |
LoseNBIX / S&P NBIX unavailable / 18.23% |
| 2018-Q32/3 |
WinNBIX / S&P 25.15% / 7.71% |
WinNBIX / S&P 517.30% / 10.21% |
LoseNBIX / S&P NBIX unavailable / 19.06% |
| 2018-Q22/3 |
WinNBIX / S&P 18.46% / 3.43% |
WinNBIX / S&P 5003.11% / 9.03% |
LoseNBIX / S&P NBIX unavailable / 14.46% |
| 2018-Q11/3 |
WinNBIX / S&P 6.88% / -0.76% |
LoseNBIX / S&P NBIX unavailable / 7.68% |
LoseNBIX / S&P NBIX unavailable / 12.46% |
| 2017-Q42/3 |
WinNBIX / S&P 26.62% / 6.64% |
WinNBIX / S&P 977.51% / 7.03% |
LoseNBIX / S&P NBIX unavailable / 13.82% |
| 2017-Q32/3 |
WinNBIX / S&P 33.22% / 4.48% |
WinNBIX / S&P 347.39% / 5.68% |
LoseNBIX / S&P NBIX unavailable / 17.57% |
| 2017-Q21/3 |
WinNBIX / S&P 6.24% / 3.09% |
LoseNBIX / S&P -57.77% / 4.83% |
LoseNBIX / S&P NBIX unavailable / 17.74% |
| 2017-Q11/3 |
WinNBIX / S&P 11.89% / 6.07% |
LoseNBIX / S&P -100.00% / 3.67% |
LoseNBIX / S&P NBIX unavailable / 13.32% |
| 2016-Q40/3 |
LoseNBIX / S&P -23.58% / 3.82% |
LoseNBIX / S&P -24.12% / 2.09% |
LoseNBIX / S&P NBIX unavailable / 7.05% |
| 2016-Q31/3 |
WinNBIX / S&P 11.42% / 3.85% |
LoseNBIX / S&P -24.12% / 0.20% |
LoseNBIX / S&P NBIX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | NBIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 10.34% | 20.78% |
| Annualized return | 10.34% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | NBIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 61.15% | 83.14% |
| Annualized return | 10.01% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | NBIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 207.34% | 319.30% |
| Annualized return | 11.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |